Actively Recruiting
Anticoagulation Profile in Pregnant Women Treated With Three Times a Day of Low Molecular Weight Heparin (LMWH)
Led by University of California, Irvine · Updated on 2025-10-29
12
Participants Needed
1
Research Sites
30 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Pregnancy increases the risk of developing blood clots by nearly five times, which can be dangerous for both mother and baby. Researchers are studying whether giving the medication Lovenox three times a day instead of the usual twice daily can help maintain more consistent blood levels and potentially reduce this risk. This study focuses on pregnant women who need therapeutic low molecular weight heparin to prevent clots during pregnancy. Participants in this study will receive Lovenox split into three doses per day for five days. The researchers will measure Factor Xa levels, an indicator of how well the medication is working, four hours after injection. This dosing schedule is being tested because changes in blood volume and kidney function during pregnancy may affect how the medication is processed. During the study, women will have their blood tested to check Factor Xa levels after each Lovenox injection. The study team will monitor these levels to understand how three times daily dosing affects medication consistency. Participation includes regular visits over the treatment period, and the research aims to gather detailed information on the medication's anticoagulation profile in pregnant women.
CONDITIONS
Brief Title
Anticoagulation Profile in Pregnant Women Treated With Three Times a Day of Low Molecular Weight Heparin (LMWH)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Nulliparous or multiparous women with single intrauterine pregnancies who require therapeutic low molecular weight heparin during their pregnancy.
- Participants must be age 18 or older.
You will not qualify if you...
- Women with multiples.
- Women less than age 18
- History of Heparin Induced Thrombocytopenia (HIT)
- Allergy to enoxaparin
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 5 days
Participants receive therapeutic Lovenox dosing split into three times a day dosing for 5 days with measurement of Factor Xa levels.
Multiple visits for dosing and blood level measurements over 5 days
Trial Site Locations
Total: 1 location
1
University of California Irvine
Orange, California, United States, 92868
Actively Recruiting
Research Team
L
Lizette Spears
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
PREVENTION
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here